help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on September 13, 2007, doi:10.1165/rcmb.2007-0232OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2007-0232OCv1
38/2/192    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Morin, C.
Right arrow Articles by Rousseau, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morin, C.
Right arrow Articles by Rousseau, E.
American Journal of Respiratory Cell and Molecular Biology. Vol. 38, pp. 192-201, 2008
© 2008 American Thoracic Society
DOI: 10.1165/rcmb.2007-0232OC

EET Displays Anti-Inflammatory Effects in TNF-{alpha}–Stimulated Human Bronchi

Putative Role of CPI-17

Caroline Morin1, Marco Sirois2, Vincent Echave2, Marcio M. Gomes3 and Eric Rousseau1

1 Le Bilarium, Department of Physiology and Biophysics, 2 Service of Thoracic Surgery, and 3 Department of Pathology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada

Correspondence and requests for reprints should be addressed to Eric Rousseau, Ph.D., Le Bilarium, Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, PQ, J1H 5N4 Canada. E-mail: Eric.Rousseau{at}USherbrooke.ca

The aim of the present study was to investigate the anti-inflammatory effects of 14,15-epoxyeicosatrienoic acid (EET) on reactivity and Ca2+ sensitivity in TNF-{alpha}–stimulated human bronchi. Tension measurements performed on either control, TNF-{alpha}–, or TNF-{alpha} + EET–pretreated bronchi revealed that 100 nM 14,15-EET pretreatments significantly reduced the reactivity of TNF-{alpha}–pretreated tissues to contractile agonists. EET also normalized the relaxing response to isoproterenol in TNF-{alpha}–treated bronchi. Pretreatment with 100 nM 14,15-EET prevented TNF-{alpha}–induced I{kappa}B{alpha} degradation, as demonstrated by an increase in I{kappa}B{alpha} protein levels on Western blot analysis. The anti-inflammatory properties of EET were mediated by the inhibition of I{kappa}B{alpha} degradation, suggesting a lower activation of NF-{kappa}B. The Ca2+ sensitivity of TNF-{alpha}–stimulated bronchi was also evaluated on β-escin–permeabilized preparations. Observed mean responses demonstrated that EET pretreatments abolished Ca2+ hypersensitivity developed by TNF-{alpha}–stimulated bronchial explants. Moreover, 14,15-EET significantly reduced PDBu-induced Ca2+ sensitivity in TNF-{alpha}–stimulated bronchi. Western blot and RT-PCR analyses revealed that CPI-17 protein and transcript levels were increased in TNF-{alpha}–treated bronchi, as opposed to being decreased in the presence of 14,15-EET. This eicosanoid also reduced U-46619–induced Ca2+ sensitivity, which is related to the activation of Rho-kinase pathway. These results were also correlated with an increase in protein staining and transcription level of p116Rip, a RhoA inhibitory-binding protein. Altogether, these data demonstrate that 14,15-EET is a potent modulator of the hyperreactivity triggered by TNF-{alpha} in human airway smooth muscle cells.

Key Words: epoxyeicosatrienoic acid • TNF-{alpha} • human bronchial smooth muscle • CPI-17 • NF-{kappa}B


CLINICAL RELEVANCE

The current research and the results obtained may be highly relevant for human diseases, such as asthma and chronic obstructive pulmonary disease.

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2008 American Thoracic Society.